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ABSTRACT
Background To analyse the scientific evidence that exists for the advertising claims made for two products containing Lactobacillus casei and
Bifidobacterium lactis and to conduct a comparison between the published literature and what is presented in the corporate website.
Methods Systematic review, using Medline through Pubmed and Embase. We included human clinical trials that exclusively measured the effect
of Lactobacillus casei or Bifidobacterium lactis on a healthy population, and where the objective was related to the health claims made for certain
products in advertising. We assessed the levels of evidence and the strength of the recommendation according to the classification criteria
established by the Oxford Centre for Evidence Based Medicine (CEBM). We also assessed the outcomes of the studies published on the website
that did not appear in the search.
Results Of the 440 articles identified, 16 met the inclusion criteria. Only four (25%) of these presented a level of evidence of 1b and a
recommendation grade of A, all corresponding to studies on product containing Bifidobacterium lactis, and only 12 of the 16 studies were
published on the corporate website (47).
Conclusions There is insufficient scientific evidence to support the health claims made for these products, especially in the case of product
containing Lactobacillus casei.
Keywords Bifidobacterium, fermented milk products, Lactobacillus casei, probiotics, systematic review
Introduction
Functional foods were ﬁrst developed in 1984 in Japan, in
response to the widespread interest in improving health and
reducing the risk of cardiovascular disease through diet.1
Thought to have more beneﬁcial health properties than con-
ventional foods, functional foods have become a business
opportunity for the food industry, which has invested millions
of dollars in their development.2 In the case of fermented
milks and yogurt, these have been produced for centuries in
the Mediterranean region, providing beneﬁts in other areas
such as body weight.3
This has been accompanied by strong marketing campaigns
using various channels to promote their beneﬁts through
health claims made in advertising. The use of health claims is
very similar to the approach used by medical corporations,
which transmit seductive messages suggesting that ‘perfect
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health’ can be achieved through the use of drugs.4,5 This
ﬂood of probiotic products with supposedly beneﬁcial and
preventative properties also entails an increasing promotion
of the ideology of health consciousness.6
Internationally, regulation of these foods is often unclear, cre-
ating an ambiguity which in practice results in lax controls.
However, the USA and Japan have led the way in this respect,
with legislation in place in both countries since 1990. They cur-
rently have two deﬁned levels of required scientiﬁc rigour:
(i) high level of scientiﬁc evidence, known as ‘signiﬁcant scientif-
ic agreement’ (SSA) in the USA and ‘Foods for Speciﬁed Health
Use’ (FOSHU) in Japan, and (ii) low level of scientiﬁc evidence,
known as ‘qualiﬁed health claims’ in the USA and ‘qualiﬁed
FOSHU’ in Japan. The European Union only has a requirement
for a high level of scientiﬁc evidence, through Regulation 1924/
2006 (sections 13 and 14),7 issued relatively recently, in 2006.8
Thus, the validity of health claims must be demonstrated to the
European Food Safety Agency (EFSA)9 in a report presenting
the scientiﬁc evidence for the supposed beneﬁcial effects that
consumption of the product has on health.
Despite the fact that the EFSA only takes a high level of
scientiﬁc evidence into account, unlike its counterparts in the
USA and Japan which also consider a lower level of evidence,
and although studies measuring observance of existing legisla-
tion on nutrition and health claims are scarce, it would never-
theless appear that there is some degree of non-compliance
on the part of food companies in this regard. Failure to meet
the requirements of the Regulation as regards certain types of
health claims, the regular occurrence of unauthorized health
claims and the less healthy nutritional proﬁle of most pro-
ducts for which nutritional and/or health claims are made,
may be creating a climate of confusion and could be mislead-
ing consumers.10
A widely cited example is the case of product containing
Lactobacillus casei and its associated controversial advertising cam-
paigns.11 In 2009, the Advertising Standards Authority (ASA) in
the UK investigated a complaint lodged by a consumer about an
advertisement in which the following message appeared: ‘scientif-
ically proven to help support your kid’s defences’, and ruled that
the advertising claim was misleading and not supported by the
studies presented, calling the French multinational to task and
ordering them to withdraw the advertisement until it had been
amended.12 Danone has used a similar approach to promoting
Actimelw as that used for other probiotics: advertisements that
depict the daily life of potential consumers, presenting the con-
sumption of a probiotic product as a dietary habit and proclaim-
ing its alleged health beneﬁts.13
In accordance with Article 13.5 of the EU Regulation,
which regulates claims supported by new scientiﬁc evidence
and/or that include an application for the protection of data
subject to intellectual property rights, the EFSA evaluates
applications on a case-by-case basis. Speciﬁcally as regards the
brands Actimel and Activia, the regulatory body has ruled
that the following claims be ‘withdrawn’: (i) A fermented milk
that contains the probiotic Lactobacillus casei DN 114001/
CNCM I-1518 Actimelw and helps to maintain [contributes
to] the intestinal defence function; (ii) A fermented milk that
includes Biﬁdobacterium lactis DN-173 010/CNCM I-2494 and
lactic acid bacteria Activiaw, and improves gastrointestinal
comfort; (iii) Activiaw improves slow transit; (iv) Actimelw
helps to strengthen the body’s natural defences; (v) Activiaw
products are fermented milks that improve digestive comfort.
With respect to Article 14, on reducing a risk factor in the
development of a disease, EFSA members considered that
there was an insufﬁcient cause–effect relationship between
consumption of this product and disease reduction to support
the following claim: Fermented milk that contains the probiotic
L. casei DN 114001/CNCM I-1518 Actimelw and reduces the
presence of Clostridium difﬁcile toxins in the gut, associated with
the incidence of acute diarrhoea. Consequently, this claim
cannot be used in advertising, either.14
At present, April 2013, advertising for the product presents
the following argument ‘Actimelw contains L. casei Danone,
Vitamin B6 and D, which support the normal function of the
immune system’ and ‘Actimelw contains the exclusive L. casei
Danone and Vitamin B6 to support the immune system and
reduce fatigue’. As can be seen, the product is enriched with vita-
mins B6 and D. According to Regulation (EC) no. 432/2012,
which establishes a list of permitted health claims for foods
other than those related to disease risk reduction and child devel-
opment and health, vitamin B6 ‘helps reduce tiredness and
fatigue’ and—together with vitamin D—‘contributes to the
normal function of the immune system’, among other proper-
ties. Thus, the health-related arguments presented in the product
advertising are in line with current legislation.
Studies have been conducted on the public’s attitude to
the consumption of probiotics. Brands such as Actimelw,
Yakultw and Benecolw are the ﬁrst to be named. When ex-
ploring public perceptions of probiotics, consumers reported
scientiﬁc uncertainty and personal fears, indicating that pur-
chasing decisions are heavily inﬂuenced by the beliefs and
feelings generated by advertising. Also of concern is the possi-
bility that the advertising of these products and their con-
sumption may produce health side effects.15 One example of
this is the feeling of being a ‘good mother’ that women report
experiencing when they purchase probiotic foods for their
families.16
The company has a large presence in the ﬁeld of nutrition
through the Danone Institute, which fosters and disseminates
scientiﬁc information that is subsequently used in advertising,
2 JOURNAL OF PUBLIC HEALTH
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
alluding to the supposedly beneﬁts. This aspect is of consider-
able importance, given the controversy elicited to date by
industry-funded science.17
Danone’s health claims are that product containing L. casei
strengthens the body’s natural defences, and product containing
B. lactis improves intestinal transit. To clarify the scientiﬁc evi-
dence supporting its advertising claims and to conduct a com-
parison between the published literature and that presented on
the company’s website,18 this paper reports a systematic analysis
of the studies that refer to the strains contained in the products
promoted on the Danone website. More speciﬁcally, the aim of
this study was to:
(a) determine the scientiﬁc evidence presented in studies to
support the health claims.
(b) compare the studies identiﬁed in a literature search with
those presented by Danone on its website and identify
any bias in the information provided.
Methods
Literature search profile
A literature search was conducted in Medline via Pubmed and
Embase between September and October, 2012. Previously
searched the Danone corporate website to identify all studies
published there on the products containing L. casei and
B. lactis. Terms were selected following a review of those used
in the studies published on Danone’s corporate website. The
terms chosen were: ‘fermented milk product’, ‘Lactobacillus
casei’ and ‘Biﬁdobacterium’. The search equation was: ([MeSH
Term] Fermented milk product) AND (([MeSH Term]
Lactobacillus casei) OR ([MeSH Term] Biﬁdobacterium)).
Inclusion and exclusion criteria
We included studies on human clinical trials, published in English
and Spanish, in which only the effect of the milk product on a
healthy population was measured, and where the objective was
related to the health claims made for the product in advertising:
improving defences (product containing L. casei ) and improved
intestinal transit (product containing B. lactis).
We excluded studies that did not meet the above criteria,
consisting of research measuring the effect of the milk product
in conjunction with a medication or other component, studies
on populations with pathologies, studies that used other pro-
biotic strains, studies using a different form of administration
to the format studied (capsules, milk products for reconstitu-
tion, cheese, cereals) and studies that measured other effects
unrelated to the health claims made for the products.
Although one of the inclusion criteria was that the studies
should have been conducted on healthy subjects, it was
decided to include two studies19,20 on people with irritable
bowel syndrome, since the advertising for the product that
containing B. lactis claims that it improves the symptoms of
this disease.
Analysis of the scientific literature
Information on the following variables was extracted from the
studies ﬁnally selected for the systematic review: authors,
journal name, year of publication, sample size, design, country
of origin of the study, outcomes, key ﬁndings and source of
funding for the study. We assessed the levels of evidence and
strength of recommendation according to the classiﬁcation cri-
teria established by the Oxford Centre for Evidence Based
Medicine (CEBM).21 Levels were classiﬁed from 1 to 5, where
Level 1a corresponded to the maximum recommendation
Grade A and Level 5 corresponded to Grade D, where the rec-
ommendation was neither endorsed nor rejected. We also eval-
uated the outcomes of the studies published on the website
which did not meet the inclusion criteria.
To help assess the quality of each article, reviewers used
CONSORT checklists. From a total of 25 topics per checklist,
each article received a score of 1 point if the publication met
the criteria and 0 point if it did not. For the quality of the arti-
cles included, see Tables 1 and 2.
Results
The initial search identiﬁed 440 articles: 395 articles in
Pubmed and 149 in Embase, of which 104 were duplicates,
leaving 45 additional articles in Embase. Following an initial
review, 420 articles were excluded, consisting of studies that
measured the effect of the milk product in conjunction with a
medication or other component (n ¼ 34, 8.1%), studies on
populations with pathologies (n ¼ 152, 36.2%), studies using
other probiotic strains (n ¼ 81, 19.3%), studies using a differ-
ent form of administration to the format studied (n ¼ 63,
15%) and studies that measured other effects unrelated to the
health claims made for the products (n ¼ 90, 21.4%) (Fig. 1).
We selected 16 studies that met the inclusion criteria, the
earliest of which was from 200135 and the most recent from
2011.29 Two of these had been conducted on children26,29
while the rest involved adults. Seven studies were conducted
exclusively on women, one on men and eight on both sexes.
Three of the studies were performed in Asia25,27,32 and the
remaining 13 in Europe. One study was written in Spanish26
and the rest (n ¼ 15) in English. The design of the 16 studies
are randomized controlled trials (RCT).
An analysis of the search results revealed that 12 of the
16 studies were cited on the corporate website. Thus, of the
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Table 1 Characteristics, results and limitations of the studies analysed on the effect of Lactobacillus casei in healthy populations
Authors Study
design
Sample
size
Consort
score
Age (sex) Outcomes Results Limitations
Fabian et al.22 RCT 33 9 22–29 years
old. (Females)
Plasma and urinary concentration
of thiamine (B1), riboflavin (B2)
and pyridoxine (B6)
No significant differences were found
between the two groups; the results
indicated that daily consumption of 200 g of
both yoghourts (probiotic and conventional)
for 2 weeks may contribute to levels of
thiamine and riboflavin.
No limitations reported.
Ortiz-Andrellucchi
et al.23
RCT 104 20 18–40 years
old. (Females)
Analysis of immune system
biomarkers (Th1/Th2, IgA, IgG,
IgE, IgM, leukocytes, IL-4)
No significant differences observed between
the treatment group and the control group
for most of the biomarkers analysed.
Relative absence of functional analyses of
T, NK and B cells.
Several subjects were lost in follow-up.
Meyer et al.24 RCT 33 15 22–29 years
old (Females)
Cytokine production No significant differences observed in
cytokine production between the group
consuming conventional yoghourt and the
group consuming yoghourt containing
L. casei.
Failure to include a control group that did
not consume yoghourt.
Takeda and
Okumura25
RCT 19 6 30–75 years
old. (Males
and females)
NK cell activity NK cell activity was significantly increased at
Week 1 (P ¼ 0.0598) and Week 3
(P ¼ 0.0050) following the start of
fermented milk intake, compared with NK
cell activity at baseline.
No limitations reported.
Tormo Carnicer
et al.26
RCT 35 15 1–3 years
old. (Males
and females)
Levels of immunoglobulin A (IgA)
secreted in saliva when fed
fermented milk with L. casei and
Streptococcus thermophilus
The group of children fed fermented milk
with L. casei demonstrated a significant
increase (P ¼ 0.0063) in IgA levels secreted
after 6 weeks of ingestion.
No limitations reported.
Morimoto et al.27 RCT 38 16 20–60 years
old. (Males)
Relationship between smoking
and NK cell activity.
NK cell activity following
consumption of fermented milk
containing L. casei
No change found in the relative proportion
of NK cells due to drinking fermented milk
containing L. casei.
No limitations reported.
Marcos et al.28 RCT 155 12 18–23 years
old. (Males
and females)
Immunological measurements
(number of lymphocytes, cytokine
production, immunoglobulin)
The treatment had a significant effect in
absolute terms on lymphocyte count after
6 weeks.
It is possible that the immunomodulatory
action of lactic acid bacteria on
lymphocyte count-influenced the CNS
through modifications in cytokine
balance.
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Table 2 Characteristics, results and limitations of the studies analysed on the effect of Bifidobacterium lactis in healthy populations
Authors Study
design
Sample
size
Consort
score
Age (sex) Outcomes Results Limitations
Tabbers
et al.29
RCT 202 23 18–60 years
old. (Males
and females)
Gastrointestinal well-being.
Frequency of gastrointestinal
symptoms.
Frequency and consistency of
stools
Stool frequency did not differ between the group
consuming fermented milk products and the
control group.
A significant difference was found in
self-reported gastrointestinal well-being and
symptoms.
Possible laxative effect of the control product
and possible loss effect in follow-up, although
this percentage was similar in both groups.
Guyonnet
et al.30
RCT 160 21 3–16 years
old. (Males
and females)
Frequency of bowel
movements.
Stool consistency
No significant difference found as regards
increased stools between the group consuming
the fermented milk product containing the
B. lactis DN-173 010 strain group and the
control group.
Limitation reported on data interpretation due to
the use of multiple statistical comparisons.
Guyonnet
et al.31
RCT 360 22 18–65 years
old. (Males
and females)
Gastrointestinal well-being.
Self-report questionnaires
measuring constipation,
diarrhoea, stomach pain and
gastrointestinal comfort
No significant difference observed in symptoms
such as constipation, diarrhoea or stomach pain
between the two groups receiving fermented
milk and the control group. A higher percentage
of the treated group were observed to report
gastrointestinal comfort than the control group.
The percentage of participants reporting an
improvement may be an overestimation, and it
should be noted that not all items showed an
improvement. Publicity may influence
participants’ expectations about the product.
Yang
et al.32
RCT 135 18 25–65 years
old (Females)
Frequency of bowel
movements and stool
consistency
Frequency of bowel movements increased
significantly after 2 weeks of consumption
(2.6+1.0 versus 2.4+0.6, P, 0.05), but no
differences were found after 1 week.
No limitations reported.
Agrawal
et al.19
RCT 41 24 20–69 years
old. (Females)
Symptoms of irritable bowel
syndrome, bloating and
intestinal transit
Intestinal transit time was significantly reduced. Lack of objective measures of results since most
of the symptoms, such as abdominal pain and
bloating are completely dependent on patient
self-reports.
Guyonnet
et al.20
RCT 276 22 18–65 years
old (Males
and females)
Frequency of bowel
movements and IBS symptoms
No significant differences found in frequency of
bowel movements or stool consistency.
An improvement was observed, however, in
symptoms.
The high placebo effect may be due in part to
advertising (TV, magazines, posters) health claims
made for fermented milk products, such as those
examined in the present study.
Meance
et al.33
RCT 159 16 50–75 years
old (Males
and females)
Intestinal transit time Significant differences found in intestinal transit
following consumption of the probiotic milk
product.
One limitation of this study was the possible
psychological effect on transit time of subjects’
awareness that they were consuming a
potentially effective product.
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47 articles available on the website, only 12 met the estab-
lished inclusion criteria, and only 7 of those demonstrated
some positive effect following consumption of milk products
enriched with probiotic strains (Tables 1 and 2). The results
for these seven articles showed that three of them concerning
the L. casei strain25,26,28 (n ¼ 3, 19%) corresponded to Level 5
and recommendation Grade D, because they were based on
circumstantial evidence and opinion, and none showed clinic-
al effects in support of the health claims made, but rather
reported effects on laboratory parameters.
In the case of the B. lactis strain19,32,33,35 (n ¼ 4, 25%), all
four studies provided evidence corresponding to Level 1b
and recommendation Grade A. For the remainder of the
studies (n ¼ 9, 56%), the results showed no differences, i.e.
only four studies provided valid scientiﬁc evidence and all
corresponded to B. lactis. The effect demonstrated in these
four studies was decreased intestinal transit time. Two of the
studies used male and female subjects,33,35 and two were per-
formed exclusively on females19,32
Another aspect analysed was the source of funding for these
studies and the relationship with the company. Company
funding was declared in 7 (44%) of the 16 studies. Two
(12.5%) stated that the company had supplied the probiotic,
another two (12.5%) reported that the company had supplied
the probiotic and at least one of the authors appeared to be
linked to the company, four (25%) did not mention funding
nor product contribution but one of the authors appeared to
be linked to the company and only one study (6%) did not
mention funding from the company nor were any of the
authors linked to the company.
Lastly, we assessed the 35 studies published on the website
that did not meet the inclusion criteria. Of these, 1 (2.9%)
corresponded to a study on animals, 13 (37.1%) to studies on
populations with pathologies, 18 (51.4%) to studies measur-
ing effects other than those stated in health claims and 3
(8.6%) measured the effect of milk product consumption on
a laboratory parameter.
Discussion
Main finding of this study
Our study reveals the limited scientiﬁc evidence in support of
the health beneﬁts attributed to these products in advertising
and marketing. The evidence for L. casei is null, while only four
studies support the health claims made for B. lactis. We conclude
that the company’s advertisements for its products are biased,
employing health claims that are not supported by sufﬁcient sci-
entiﬁc evidence based in these ingredients. Furthermore, the
scientiﬁc material published on their corporate website is not
related to the health claims used to advertise the milk products,
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and consumers may be confound into believing that it constitu-
tes sufﬁcient evidence for the consumption of these widely sold
and advertised products, which could generate side effects.
These results strongly suggest the need for new legislation on
health claims made for food products, which as a minimum
should prevent conﬂicts of interest.
The small number of articles found, which met the inclusion
criteria and were also published on the company’s website (12
of the 47 articles published on the website), could be a reﬂec-
tion of the diversity of objectives reported in studies on the
website, i.e. mainly studies testing the effect of probiotic strains
on speciﬁc pathologies or studies measuring an aspect unre-
lated to the health claims made for the product in question.
What is already known on this topic
The strong presence and position in the market of these pro-
ducts, due, among other factors, to their advertising, renders
this information of particular importance. The health claims
used in this advertising are based on studies conducted by the
company. However, as our study reveals, there is a worrying
paucity of scientiﬁc evidence for these claims, leading to the
conclusion that there is an information gap between the
advertising message and the expectations it fosters in potential
consumers. Thus arises the controversial subject of ‘nutrition-
al altruism’, whereby consumers feel good about buying these
products for their families as a result of the health claims
made in advertising, which are not always supported by sound
scientiﬁc evidence.16
The results of a recent study analysing current regulations
in the European Union and the USA are consistent with the
ﬁndings reported here, namely that probiotic product adver-
tising includes claims that the consumption of these products
can confer health beneﬁts. Although some of these claims
may be valid, many have not been substantiated: the claims
made for some products are based on insufﬁcient research
or weak studies. Nevertheless, consumers report that the
product is good for them.36
What this study adds
The lack of a clear deﬁnition of probiotics in the present regu-
latory framework, and the ease with which these can be
placed on the market, yielding enormous economic beneﬁts
to companies with minimal investment in research, highlights
the importance of formulating clear international standards
References located 
(n = 440)
References excluded
according to
exclusion criteria
(n = 382)
Full articles retrieved for 
reading and analysis 
(n = 54)
Articles not found 
(n = 4)
Articles excluded due
to measuring other
effects unrelated to the
health claims made for
the products (n = 38)
Articles finally included 
(n = 16)
Studies in which the effect of
the milk product was measured
in conjunction with a medication
or other component (n = 34)
Study on populations with
pathologies (n = 152)
Studies that used other
probiotic strains (n = 81)
Studies that used a different
form of administration to the
format studied (n = 63)
Studies that measured other
effects unrelated to the health
claims made for the products
(n = 52)
Articles
Bifidobacterium 
lactis (n = 9)
Articles
Lactobacillus 
casei (n = 7)
Fig. 1 Diagram of the systematic review process.
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and the need for more rigorous and high-quality research.37
The messages and arguments given today in much food ad-
vertising actually require much more quality scientiﬁc evi-
dence to support the use of such health claims.
The aim of our study was to contribute to the scant available
evidence on the subject and encourage the industry to give real
importance to the use of health claims with good-quality scien-
tiﬁc evidence to deliver clear messages to the public. We believe
that companies have the necessary tools to accomplish this and
hope that this situation will improve in the near future.
Limitations of this study
In the present study, our analysis was limited to those studies
in which there was a relationship between the objective and
the health claim made for the product in question; this ap-
proach has enabled us to analyse the supposed efﬁcacy of the
milk product in a speciﬁc context and to determine consu-
mers’ expectations of these products at the time of purchase.
We have analysed the studies of the corporate website of
one of the most important companies; however, there are
other companies that also advertise products containing these
substances. Future studies should look at advertising on the
website of these companies.
It is also possible that the literature search conducted in
this study was biased due to the exclusive inclusion of articles
published in journals indexed by PubMed and Embase.
However, the scientiﬁc literature recommends the use of
these two databases for literature searches.38
Conclusions
The fact that such an important multinational company uses
health claims based on insufﬁcient supporting scientiﬁc evidence
should be borne in mind by policymakers and the competent au-
thorities, who should amend the pertinent regulations to achieve
higher standards as regards greater transparency in the food indus-
try. Health professionals should also be aware of the magnitude of
the health claims made by the food industry in advertising. This is
important when recommending this type of food or warning
about possible risks, e.g. the excessive use made of them or their
use as a replacement for medication prescribed by a professional,
due to the huge trust consumers place in advertising messages
that can cause confusion or, worse, be misleading.
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